✨ Free AI Report
Opus Genetics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Opus Genetics, Inc.
Company Research

Opus Genetics, Inc.: Business Overview, Financials & Competitive Analysis

Opus Genetics, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Clinical-stage gene therapy play with differentiated IRD pipeline but meaningful execution and capital risk ahead. Opus Genetics demonstrates solid clinical progress with FDA acceptance of its lead program and a diversified pipeline, but faces significant execution risk as a pre-revenue clinical-stage biotech. Strong year-to-date stock performance (+121.89% in 2026).

What is Opus Genetics, Inc.'s industry? Opus Genetics, Inc. (opusgtx.com) operates in Gene Therapy. AskCyborg classifies Opus Genetics, Inc. under Gene Therapy in its company registry.

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), with durable, one-time treatments desig...

5/ 10Mixed

Cyborg Score thesis

Clinical-stage gene therapy play with differentiated IRD pipeline but meaningful execution and capital risk...

Read the full analyst-debate transcript →
Industry Gene Therapy
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Opus Genetics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Opus Genetics, Inc.

AskCyborg analysts argue the bull and bear cases for Opus Genetics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Opus Genetics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Opus Genetics, Inc. Overview

Pro stress-test →

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), with durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The company is advancing a pipeline of AAV-based gene therapy candidates targeting multiple genetic causes of retinal degeneration.

Strategic Profile

Pro stress-test →

The company's pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. OPGx-LCA5 has been accepted to FDA's Rare Disease Evidence Principles (RDEP) Program and is enrolling its pivotal trial, while RDH12, MERTK and RHO programs are expected to advance to clinical testing within the next 12 months.

Competitive Landscape

Pro stress-test →

Opus Genetics competes in the rare genetic ophthalmology and gene therapy space against established biotech companies and emerging rivals pursuing retinal gene therapy programs. Direct competitors include companies developing AAV-based therapies for similar indications, as well as pharmaceutical firms exploring alternative modalities (small molecules, antisense) for inherited retinal diseases.

Industry Context

Opus Genetics, Inc. operates in Gene Therapy.

Key facts

Headquarters: Research Triangle Park, North Carolina, US · Employees: Not publicly disclosed · Revenue: Estimated $9.9M-$14.2M (pre-commercial, minimal product revenue) · Market cap: $355M-$387M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Opus Genetics, Inc..

  • Opus Genetics is a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases (IRDs), with pipeline emphasis on ophthalmic treatments targeting severe visual disorders.
  • OPGx-LCA5, the lead program for Leber congenital amaurosis type 5, received FDA RDEP (Rare Disease Evidence Principles) program acceptance on May 4, 2026, enabling expedited regulatory collaboration and potential single-study approval pathway.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • August 2026Filed $300M shelf registration and $125M ATM stock offering plan
  • September 2026Added to S&P Global BMI Index
  • +1 moreTrack every material event for Opus Genetics, Inc. as it happens. Explore monitoring →
Get alerted when Opus Genetics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Lexeo TherapeuticsGene therapy company focused on ophthalmic indications and retinal disease treatment.→Solid BiosciencesGene therapy platform company developing treatments for genetic diseases.→Rapt TherapeuticsClinical-stage biotech company in pharmaceutical products sector.→Korro BioGene therapy biotech company operating in therapeutic development.→

Compare Opus Genetics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Opus Genetics, Inc. operates in Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Opus Genetics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Opus Genetics, Inc. and its top competitor on Cyborg Score”
“What did Opus Genetics, Inc. do this quarter?”
“Is Opus Genetics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Opus Genetics, Inc. do?+
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), with durable, one-time treatments desig...
What is Opus Genetics, Inc.'s Cyborg Score?+
Opus Genetics, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Opus Genetics, Inc.'s main competitors?+
Named competitors include Lexeo Therapeutics, Solid Biosciences, Rapt Therapeutics, Korro Bio. The full competitive landscape is in the AskCyborg report.
How can I get the full Opus Genetics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Opus Genetics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Opus Genetics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4uniQure N.V.6Lexeo Therapeutics